A recent phase 3 trial of another "biologic" with some promise

Bens Friends Sjogrens Articles, News and Research
1

Here is the full article of a recent phase 3 trial comparing methtotrexate with tofacitinib (where do they get these names ? :) )

It seems to hold some promise especially as it is targetting a different area of the T cell functionality.

It may also have some relevance to SS especially extra glandular symptoms?

Slight downside is increased infections ude to immuno suppression.

http://www.nejm.org/doi/full/10.1056/NEJMoa1310476#Discussion=&t=articleTop

2

Thank you, sounds like good news.

3

Yes unfortunately as is expected when immuno supressing the T cell response there is an icreased risk of infection and carcinomas but this is interesting as it is targetting a different site on the T cell to other treatments as we improve the genomics of AI then perhaps we can imorove the hit rate and redcue the adverse events?

4

I just saw this post, thanks, I’ll have a look!